retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Survodutide vs. Retatrutide for Weight
Description
Dose-dependent increases in fasting insulin and C-peptide were observed, with maximum levels seen at 24 and 48 hours, returning to near baseline levels by Day 15
Cost-per-mg varies 24 across suppliers for identical peptides
.webp)
Additionally, brands are starting to take notice of shifting dining habits among GLP-1 users
Not much else to say honestly
